<DOC>
	<DOCNO>NCT01780051</DOCNO>
	<brief_summary>This phase-1 , single center , open-label , randomize , single-dose , 2-way crossover study . The objective study compare pharmacokinetic property co-administration Repaglinide 2mg Metformin hydrochloride 500mg administration combination preparation Repaglinide 2mg Metformin hydrochloride 500mg 50 healthy male volunteer .</brief_summary>
	<brief_title>A Pharmacokinetic Study Compare Co-administration Repaglinide Metformin HCl Administration Combination Preparation Those Two Components</brief_title>
	<detailed_description>This phase-1 , single center , open-label , randomize , single-dose , 2-way crossover study . The objective study compare pharmacokinetic property co-administration Repaglinide 2mg Metformin hydrochloride 500mg administration combination preparation Repaglinide 2mg Metformin hydrochloride 500mg 50 healthy male volunteer . - All subject admit one day prior schedule study date 4pm Chonbuk National University Hospital Clinical Trial Center serve dinner . After dinner , keep fast , allow drink water 8am study date . - According randomly designate order , subject administrate study reference product 240mL water 9am ( ±2hours ) first date study . The study reference product swallow completely , chew swallow . - Study product : Repanorm M 2/500mg ( Dalim BioTech Co. , Ltd. ) - Reference product : Metformin HCl 500mg tablet , Repaglinide 2mg tablet - Subjects fast 4 hour post administration study reference drug ( water intake allow 1 hour administration ) , follow standardize lunch four hour dinner 9 hour later time administration - Assessment laboratory test perform accordance schedule write protocol - After 7 day withdrawal period , 2nd study period do 9am ( ±2hours ) . In contrast 1st period , Sequence B receive study product 1st period take reference drug 2nd period , group Sequence A receive reference drug take study drug . The step administration drug process test 1st period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Healthy male volunteer age 20 55 year screen 2 . Subject Body Mass Index ( BMI ) range 17.5 30.5kg/m2 body weight 45kg 3 . Signed informed consent date signature 4 . With ability comply schedule visit , treatment plan ; laboratory test process . 1 . Positive blood , kidney , endocrine , lung , gastrointestinal , cardiovascular , hepatic , psychiatric , nervous , allergy ; past present disease history symptom clinically significant . 2 . Any condition likely affect drug absorption . ex ) gastrectomy 3 . Positive urine drug test 4 . History drink alcohol 12 ounce ( 360mL ) beer , 1.5 ounce ( 45mL ) liquor ; 21 drinks/week ( 1drink = 5 ounce ( 150mL ) wine ) 6months prior screen 5 . Participation clinical study within 2months prior schedule study drug administration 6 . With Blood pressure ≥ 160 mmHg ( Systolic blood pressure ) ≥ 90 mmHg ( Diastolic blood pressure ) sit position screening time . 7 . History serious substance alcohol abuse within one year prior screen 8 . Use drug know significantly induce inhibit drug metabolize enzyme within 30days prior schedule study drug administration 9 . Cigarette smoke 20 stick per day . 10 . Use prescription drug counter drug within 10days quintuple half life ( whichever longer ) prior schedule study drug administration 11 . Donation whole blood within 2months blood product within 1month , prior schedule study drug administration 12 . Disability comply guideline write protocol 13 . Severe acute/chronic medical , physical disorder laboratory test abnormality likely alter study result increase risk participate study study drug administration 14 . Hypersensitivity chief component excipient Repaglinide 15 . History hypersensitivity Metformin Biguanide class drug 16 . With renal failure renal inadequacy cause cardiovascular shock , acute myocardial infarction sepsis 17 . With Congestive heart failure undergoing drug treatment . 18 . Patients undergo radioactive iodine uptake test , intravenous urography , intravenous cholangiography , angiography , compute tomography use radioactive iodine 19 . Patients type 1 diabetes , acute chronic metabolic acidosis include diabetic ketoacidosis associate without coma 20 . With serious infection trauma 21 . Malnutrition , starvation ; weakness ; pituitary insufficiency adrenal insufficiency 22 . Patients hepatic failure , pulmonary infarction , serious pulmonary dysfunction , condition associate hypoxemia , alcohol abuser , dehydration , diarrhea ; vomit gastrointestinal disease 23 . Proven unsuitable participate clinical study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>